Outcome following a short period of adalimumab dose escalation as rescue therapy in psoriatic patients

Autor: Laura Bigi, Annamaria Offidani, Andrea Conti, Alfredo Giacchetti, Laura Rosa, Alberta Bettacchi, Federico Bardazzi, Lidia Sacchelli, Shaniko Kaleci, Anna Campanati, Claudia Lasagni, M. Nicolini, Sergio Di Nuzzo, Vito Di Lernia
Rok vydání: 2020
Předmět:
Zdroj: European Journal of Dermatology. 30:159-164
ISSN: 1952-4013
1167-1122
DOI: 10.1684/ejd.2020.3751
Popis: Advances in biologic treatments have led to a new therapeutic frontier for moderate-to-severe psoriasis. Nevertheless, the efficacy of anti-TNFα decreases with time, requiring adjustments to maintain valuable Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) responses. To evaluate the efficacy and safety of adalimumab dose escalation (40 mg, subcutaneous, once a week for 24 weeks) in psoriatic adult patients with secondary loss of response (PASI ≥50 to ≤75 or PASI≥75 and DLQI ≥5). A multicentre, observational study involving different Italian third-level referral centres for psoriasis enrolled a total of 64 adult patients with moderate-to-severe psoriasis who were treated with adalimumab and experienced a secondary loss of response. Primary end-points were PASI< 75 or PASI ≥50 to ≤ 75 with DLQI ≤ 5, and the secondary end-point was the ability to maintain a therapeutic response, resuming adalimumab every other week. At Week 16 and Week 24, 29/64 (45.3%) and 35/64 (54.6%) responded based on PASI, and mean DLQI was 4.9 and 4.09, respectively. At Week 36 and Week 48, 45.3% and 28.1% patients achieved the second end-point, respectively. No adverse events were recorded except for one patient with recurrent tonsillitis. Adalimumab escalation could be considered in cases with loss of response before switching to alternative biologic therapy.
Databáze: OpenAIRE
Externí odkaz: